You must have javascript enabled on your browser to get the best out of this website and to request reports.

If you are unsure how to enable javascript in your browser, please consult the Help menu in your browser. This website may also be able to show you how to enable javascript:

Latest News and Archive

EJCMO: Clinical Debate Series: Emerging Evidence in Treating Patients with Refractory Chronic Lymphocytic Leukaemia (CLL)


with Drs Peter Hillmen, Stephan Stilgenbauer, William Wierda and Susan O'Brien

Patients with refractory chronic lymphocytic leukaemia (CLL) have an unfavourable prognosis and continue to pose a daunting challenge for the haematologist. In particular, we are now seeing refractoriness not just with fludarabine but also fludarabine-combinations (e.g. cyclophosphomide, rituximab and alemtuzumab). But there are emerging treatment options for these patients beyond enrolling them in clinical trials. Drs Peter Hillman, Stephan Stilgenbauer, William Wierda and Susan O'Brien discuss and debate emerging evidence in treating patients with refractory CLL in a 4 part video series.

Please visit the latest online EJCMO newsletter here for more debate, interviews and podcasts.

26 Apr 2012

Click here to return to the Latest News page

About the EACR

Advancing cancer research - from basic research to prevention, treatment and care

The European Association for Cancer Research was established in 1968 and the membership is over 9,000. The Association offers opportunities for:

  • Communication
  • Biennial congresses, educational courses, scientific meetings and special conferences
  • Travel fellowships and bursaries
  • Awards and acknowledgement
  • Advance information and professional support
  • Contacts and opportunities for collaborative research




Sustaining Members